Company news
UroGen Pharma Ltd. news in 2020
UroGen Pharma Ltd.'s news releases, calls and decks from 2020, newest first.
UroGen Pharma Announces Podium Presentation of Final Jelmyto® Data From Pivotal OLYMPUS Trial at the Annual Meeting of the Society of Urologic Oncology
December 2, 2020
Complete and Durable Responses Observed in OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
November 16, 2020
Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for UroGen’s Jelmyto® Effective January 1, 2021
November 10, 2020
UroGen Pharma Announces November 2020 Conference Schedule
November 9, 2020
UroGen Pharma Reports Third Quarter 2020 Financial Results and Recent Corporate Developments
November 8, 2020
UroGen Pharma to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020
November 1, 2020
UroGen Pharma Announces September 2020 Conference Schedule
September 9, 2020
UroGen Pharma Expands Executive Team to Accelerate Platform Innovation and Drive Commercial Growth
September 8, 2020
UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel™ Hydrogel Formulation in Combination with BOTOX® (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary Incontinence
August 26, 2020
UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments
August 9, 2020
UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
August 2, 2020
UroGen Pharma to Present at Jefferies Virtual Healthcare Conference
May 31, 2020
UroGen Pharma Announces First Presentation of Data from Phase 2b Study of UGN-102 in Patients with Difficult to Treat Type of Bladder Cancer
May 14, 2020
UroGen Announces Positive Data from Pivotal OLYMPUS Trial Evaluating Jelmyto™ in Patients with Low-Grade Upper Tract Urothelial Cancer
May 14, 2020
UroGen Pharma Reports First Quarter 2020 Financial Results and Recent Corporate Developments
May 6, 2020
UroGen Pharma to Report First Quarter 2020 Financial Results On Thursday, May 7, 2020
April 30, 2020
The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial
April 29, 2020
UroGen Pharma Receives U.S. FDA Expedited Approval for Jelmyto™, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer
April 14, 2020
UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
April 2, 2020
UroGen Pharma Promotes Key Personnel Focused on Commercial Operations and Expanded Clinical Development
March 22, 2020
UroGen Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments
March 1, 2020
UroGen Pharma Announces March 2020 Investor Conference Schedule
February 24, 2020